Myotolid, (100 mg + 2.5 mg) /mL, solution for injection

Myotolid, 100 mg + 2.5 mg, solution for injection (tolperisone + lidocaine) is indicated in adults for:

-           Symptomatic treatment of spasticity due to stroke. 

-           Treatment of moderate and severe myofascial pain syndrome (including muscle spasm in dorsopathy).

Tolperisone Hydrochloride is a centrally acting muscle relaxant. It has a membrane stabilizing, local anesthetic effect, inhibits the conduction of nerve impulses in the primary afferent fibers and motor neurons, which leads to blocking of spinal mono- and polysynaptic reflexes. Presumably, tolperisone mediates blocking the release of mediators by inhibiting the entry of calcium ions into synapses. It inhibits the conduction of excitation along the reticulospinal pathway in the brain stem.

Regardless of the effect on the central nervous system, it enhances peripheral circulation. This action is not associated with the effect of the drug on the central nervous system and may be due to the weak antispasmodic and antiadrenergic action of tolperisone.

Lidocaine Hydrochloride has only a local anesthetic effect and does not have systemic effects when is administered according to the instruction.